Zimmer Biomet (ZBH)
(Delayed Data from NYSE)
$90.62 USD
-1.03 (-1.12%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $90.59 -0.03 (-0.03%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ZBH 90.62 -1.03(-1.12%)
Will ZBH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ZBH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZBH
Will Canopy Growth Corporation (CGC) Report Negative Earnings Next Week? What You Should Know
Analysts Estimate Zimmer Biomet (ZBH) to Report a Decline in Earnings: What to Look Out for
ZBH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can ISRG's Strong Q2 Procedure Volume Translate Into Durable EPS Upside?
ZBH Stock Set to Benefit From New Monogram Technologies Buyout Deal
ISRG Expands Installed Base, But Is Utilization Keeping Pace?
Other News for ZBH
Franklin Mutual Quest Fund Q2 2025 Commentary
What Does the Market Think About Zimmer Biomet Holdings?
Franklin Mutual Shares Fund Q2 2025 Commentary
Franklin Mutual Global Discovery Fund Q2 2025 Commentary
P/E Ratio Insights for Zimmer Biomet Holdings